Latest Genzyme Canada Stories
MISSISSAUGA, ON, Feb. 27, 2014 /CNW/ - Genzyme, a Sanofi company, today announced the Canadian availability of (Pr)LEMTRADA(TM) (alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. LEMTRADA 12 mg has a dosing and administration schedule of two annual treatment courses. The first...
- The offense of persistently instigating lawsuits, typically groundless ones.
- An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
- Sale or purchase of positions in church or state.